Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free ... MarketWatch Immunomedics, Inc. (NASDAQ:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the ... |
